The FDA has approved a second Alzheimer’s drug that can slow the onset of the disease and it is expected that the drug will be approved for use in the EU in the coming months. To the possible impact this could have Luke O'Neill is joined by Prof Sean Kennelly, Clinical Director of the Institute of Memory and Cognition in Tallaght University Hospital & Newstalk presenter, Clare McKenna.
Alzheimer's drug approvals & possible impact for patients
The FDA has approved a second Alzheimer’s drug that can slow the onset of the disease and it is...
09.40 20 Jul 2024